IL17A and COVID-19: The multisystemic immune dysregulation observed in patients with moderate or severe COVID-19 includes an increase in various pro-inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFα), interferon-gamma (IFNγ), and IL-17, compared to healthy volunteers10,37–40, as also observed in this study.